AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

SQ tocilizumab products - Giant Cell Arteritis (GCA)

<u>Drug Requested</u> : select one drug below	(Pharmacy)
□ Actemra® SQ (tocilizumab)	□ Tyenne® SQ (tocilizumab-aazg)
MEMBER & PRESCRIBER INFO	ORMATION: Authorization may be delayed if incomplete.
Member Name:	
Member AvMed #:	
Prescriber Name:	
Prescriber Signature:	
Office Contact Name:	
Phone Number:	Fax Number:
DRUG INFORMATION: Authoriza	
Drug Name/Form/Strength:	
Dosing Schedule:	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight (if applicable):	Date weight obtained:
Recommended Dosage : 162 mg given tapering course of glucocorticoids	once every week as a subcutaneous injection, in combination with a
	ow all that apply. All criteria must be met for approval. To on, including lab results, diagnostics, and/or chart notes, must be
Initial Authorization: 12 months	
 □ Prescribed by or in consultation with □ Neurologist □ Ophthalmologist □ Rheumatologist 	of the following:

(Continued on next page)

1

	Member has diagnosis of Giant Cell Arteritis (GCA) with large vessel arteritis that has at some point been verified with biopsy or with imaging of the large vessels (e.g., color Doppler ultrasound [CDUS], MRI, PET-CT, or CT angiography) Member is at least 18 years of age Member has tried one systemic corticosteroid uthorization: 12 months. Check below all that apply. All criteria must be met for approval. To
	ort each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must ovided or request may be denied.
	Member has experienced disease response as indicated by improvement in signs and symptoms compared to baseline such as headache, temporal artery tenderness, visual symptoms, inflammatory parameters (e.g., erythrocyte sedimentation rate [ESR], C-reactive protein), improvement of periodic imaging studies (color Doppler ultrasound [CDUS], MRI, PET-CT, or CT angiography
Medication being provided by Specialty Pharmacy – Proprium Rx	
	Use of samples to initiate therapy does not meet step edit/preauthorization criteria.** evious therapies will be verified through pharmacy paid claims or submitted chart notes.